GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2016
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Text-mining clinically relevant cancer biomarkers for curation into the CIViC database.Genome medicine · 2019Pooled it
- Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.Journal of hematology & oncology · 2018Trial
- Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.Future oncology (London, England) · 2018Trial
- Practical Guide for Managing Philadelphia-Negative Myeloproliferative Neoplasms in Patients with Organ Dysfunction.Oncology · 2026Review
- Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera.Cancer research and treatment · 2026Article
- JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes.Blood advances · 2023Article
- Disease Modification in Myelofibrosis: An Elusive Goal?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells.Annual review of medicine · 2022Review
- Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.Current hematologic malignancy reports · 2021Review
- Successive development of ischemic stroke and hemorrhagic stroke in a patient with essential thrombocythemia: a case report.The Journal of international medical research · 2021Article
- Being a Myeloproliferative Patient in COVID-19 Era: The Mytico Study.Frontiers in oncology · 2021Article
- Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation.Journal of thrombosis and thrombolysis · 2020Article
- Investigation and management of erythrocytosis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020Review
- JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.HemaSphere · 2020Review
- Management of myelofibrosis after ruxolitinib failure.Leukemia & lymphoma · 2020Article
- Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group.JCO oncology practice · 2020Review
- Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.Clinical lymphoma, myeloma & leukemia · 2020Observational
- Mutational profiling in myelofibrosis: implications for management.International journal of hematology · 2020Review
- The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.Therapeutic advances in hematology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 1 institution in 1 country.
Funding
Abstract
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.